Clinical Trials in Salt Lake City

Showing 4841-4860 of 16,694 trials

Mechanisms of CBD for Chronic Pain

NCT04044729

This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.

Chronic Pain

University of Utah24 participantsStarted Mar 2020

Salt Lake City, Utah, United States

TERMINATEDPhase 1< 1 mile

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

NCT05609942

The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are: * Determine Recommended Dose of elenestinib (BLU-263) monotherapy for participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) monotherapy * Efficacy of elenestinib (BLU-263) monotherapy in participants with AdvSM * Determine Recommended Dose of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) in combination with azacitidine * Efficacy of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.

Advanced Systemic Mastocytosis

Blueprint Medicines Corporation9 participantsStarted Sep 2023

Palo Alto, California, United States • Boston, Massachusetts, United States • Ann Arbor, Michigan, United States +8 more locations

Mechanisms of CBD for Chronic Pain

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Find Trials by Condition in Salt Lake City

A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

The SHUNT-V Study for Varices

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

MRI to Characterize and Predict CF Liver Disease in PUSH Cohort

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Amivantamab in Adenoid Cystic Carcinoma

Calypso Knee System Clinical Study

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors